Alberto Alvarez-Larrán Selected Research

Alberto Alvarez-Larrán Research Topics

Disease

13	Thrombosis (Thrombus) 01/2022 - 02/2006
13	Essential Thrombocythemia 01/2021 - 02/2009
10	Polycythemia Vera 01/2022 - 02/2012
9	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 10/2003
8	Hemorrhage 01/2022 - 10/2005
8	Primary Myelofibrosis (Myelosclerosis) 10/2021 - 11/2004
7	Neoplasms (Cancer) 01/2022 - 06/2011
5	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 08/2010
3	Anemia 04/2017 - 11/2015
3	Thrombotic Thrombocytopenic Purpura 10/2009 - 01/2003
2	Second Primary Neoplasms (Neoplasms, Second) 01/2022 - 04/2020
2	Disease Progression 01/2022 - 08/2015
2	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 11/2020 - 11/2010
2	Thrombocytopenia (Thrombopenia) 01/2016 - 01/2003
2	Philadelphia Chromosome 05/2015 - 11/2012
2	Exanthema (Rash) 11/2010 - 06/2006
2	Fever (Fevers) 10/2009 - 06/2006
1	Skin Neoplasms (Skin Cancer) 01/2022
1	von Willebrand Diseases (von Willebrand's Disease) 09/2021
1	Thrombocytosis (Thrombocythemia) 09/2021
1	Hemolysis 11/2020
1	Aneuploidy (Aneuploid) 10/2019
1	Xanthomatosis (Xanthoma) 01/2017
1	Atrial Fibrillation 10/2016
1	Rupture 11/2015
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 06/2011
1	Lymphoma (Lymphomas) 03/2011
1	Genomic Instability 07/2010
1	Activated Protein C Resistance (APC Resistance) 02/2009
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 06/2006
1	Ascites 10/2005
1	Neutropenia 10/2003
1	Hemolytic Anemia 01/2003
1	Splenomegaly 09/2002

Drug/Important Bio-Agent (IBA)

6	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2022 - 02/2012
4	Rituximab (Mabthera)FDA Link 11/2020 - 06/2006
4	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2016 - 06/2013
4	Imatinib Mesylate (Gleevec)FDA Link 02/2012 - 10/2003
3	Tyrosine Kinase InhibitorsIBA 01/2022 - 05/2015
3	anagrelide (Agrylin)FDA LinkGeneric 09/2021 - 11/2012
3	insulin receptor-related receptor (IRR)IBA 04/2020 - 08/2010
3	Biological ProductsIBA 04/2020 - 03/2015
3	Proteins (Proteins, Gene)FDA Link 08/2011 - 07/2006
3	thiamine triphosphorate (TTP)IBA 10/2009 - 01/2003
2	Biomarkers (Surrogate Marker)IBA 11/2020 - 06/2011
2	Hemoglobins (Hemoglobin)IBA 11/2020 - 11/2012
2	Erythropoietin FDA Link 04/2017 - 11/2004
2	Danazol (Azol)FDA LinkGeneric 11/2015 - 06/2005
2	Phosphotransferases (Kinase)IBA 11/2012 - 07/2010
2	P-SelectinIBA 02/2009 - 02/2006
1	LigandsIBA 01/2022
1	ruxolitinibIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Natural Killer Cell ReceptorsIBA 01/2022
1	Interferon-alpha (Interferon Alfa)IBA 09/2021
1	asciminibIBA 01/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2020
1	Intravenous Immunoglobulins (IVIG)FDA Link 11/2020
1	ChromatinIBA 10/2019
1	HematinicsIBA 04/2017
1	AnticoagulantsIBA 10/2016
1	Prednisone (Sone)FDA LinkGeneric 01/2016
1	Messenger RNA (mRNA)IBA 08/2015
1	Vitamin K FDA Link 06/2015
1	bosutinibIBA 05/2015
1	CalreticulinIBA 03/2015
1	Busulfan (Busulfex)FDA Link 12/2014
1	Urea TransportersIBA 08/2013
1	Codon (Codons)IBA 05/2012
1	pro-brain natriuretic peptide (1-76)IBA 06/2011
1	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2011
1	liposomal doxorubicin (Doxil)FDA Link 03/2011
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 08/2010
1	prothrombin fragment 1IBA 02/2009
1	Factor V (Coagulation Factor V)IBA 02/2009
1	Blood Coagulation Factors (Coagulation Factor)IBA 02/2009
1	AntigensIBA 02/2009
1	Thromboplastin (Tissue Factor)IBA 02/2009
1	von Willebrand FactorIBA 02/2009
1	ThrombomodulinIBA 02/2009
1	SelectinsIBA 02/2009
1	CD40 Ligand (CD40L)IBA 02/2009
1	fibrin fragment D (D-dimer)IBA 02/2009
1	Methylene Blue (Methylthioninium Chloride)FDA Link 10/2008
1	Inosine Triphosphate (ITP)IBA 06/2006
1	LipopolysaccharidesIBA 02/2006
1	AndrogensIBA 06/2005
1	SurvivinIBA 05/2005
1	InterferonsIBA 10/2003
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 09/2002

Therapy/Procedure

18	Therapeutics 01/2022 - 10/2003
3	Plasma Exchange 11/2020 - 10/2008
3	Drug Therapy (Chemotherapy) 01/2017 - 03/2011
1	Cell Transplantation 10/2021
1	Splenectomy 11/2020
1	Secondary Prevention 06/2015
1	VAP-cyclo protocol 03/2011
1	Transjugular Intrahepatic Portasystemic Shunt 10/2005
1	Surgical Portasystemic Shunt (Portosystemic Shunt) 10/2005